Clinical development of anti-RANKL therapy

@article{Schwarz2007ClinicalDO,
  title={Clinical development of anti-RANKL therapy},
  author={Edward M Schwarz and Christopher T. Ritchlin},
  journal={Arthritis Research & Therapy},
  year={2007},
  volume={9},
  pages={S7 - S7}
}
The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. This has provided an ideal target for therapeutic interventions in metabolic bone disease. As described in previous reviews in this supplement, RANKL signaling is required for osteoclast differentiation, activation, and survival. Furthermore, in vivo inhibition of RANKL… CONTINUE READING